Literature DB >> 21547274

Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions.

James L Megna1, Thomas L Schwartz, Umar A Siddiqui, Mariela Herrera Rojas.   

Abstract

BACKGROUND: An epidemic of overweight and obesity in the United States has had profound effects on the health of the general population, with consequent development of metabolic syndrome and related morbidity and mortality. However, these effects have been more widespread among adults with serious and persistent mental illness.
METHODS: A literature search was conducted using the PubMed and Ovid databases. Terms used, in varying combinations, were schizophrenia, schizoaffective disorder, bipolar disorder, obesity, atypical antipsychotic, diabetes mellitus, hyperlipidemia, and metabolic syndrome. Of 103 articles generated, 71 were deemed pertinent to the current study. One reference was decided upon based on personal communication.
RESULTS: Both nonpharmacologic and pharmacologic factors contribute to obesity development in adults with serious and persistent mental illness. Consequently, similarly targeted nonpharmacologic and pharmacologic interventions have been used to mitigate against body weight gain. Although the results obtained thus far are promising, effect sizes only in the low to medium range have been realized, with nonpharmacologic interventions demonstrating slight superiority.
CONCLUSIONS: Improved therapeutic methods are needed to address the effects of obesity on individuals with serious and persistent mental illness. Factors that will likely contribute to such advancement are a better understanding of the mechanisms involved, earlier intervention, and adequately powered, randomized controlled trials of sufficient duration, with baseline body weight as a covariate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547274

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  16 in total

1.  Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways.

Authors:  A Chakraborty; C Latapy; J Xu; S H Snyder; J-M Beaulieu
Journal:  Mol Psychiatry       Date:  2013-02-26       Impact factor: 15.992

Review 2.  Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism.

Authors:  M Koch; T L Horvath
Journal:  Mol Psychiatry       Date:  2014-04-15       Impact factor: 15.992

3.  Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.

Authors:  Michael J Bly; Stephan F Taylor; Gregory Dalack; Rodica Pop-Busui; Kyle J Burghardt; Simon J Evans; Melvin I McInnis; Tyler B Grove; Robert D Brook; Sebastian K Zöllner; Vicki L Ellingrod
Journal:  Bipolar Disord       Date:  2013-12-13       Impact factor: 6.744

4.  The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.

Authors:  Maria Ferrara; Anya Umlauf; Chelsea Sanders; Jonathan M Meyer; John Allen McCutchan; Nichole Duarte; Joseph Hampton Atkinson; Igor Grant; Ronald J Ellis
Journal:  Psychiatry Res       Date:  2014-04-18       Impact factor: 3.222

5.  Increasing Psychiatrists' Role in Addressing the Cardiovascular Health of Patients With Severe Mental Illness.

Authors:  Martha Ward
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

6.  Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.

Authors:  Kaoru Noda; Takehiro Kato; Nao Nomura; Mayu Sakai; Sodai Kubota; Tokuyuki Hirose; Yanyan Liu; Yoshihiro Takahashi; Ken Takao; Masami Mizuno; Takuo Hirota; Tetsuya Suwa; Yukio Horikawa; Daisuke Yabe
Journal:  Diabetol Int       Date:  2022-06-15

7.  Weight reduction among people with severe and persistent mental illness after health behavior counseling and monitoring.

Authors:  Matthew Katekaru; Carol E Minn; Ann M Pobutsky
Journal:  Hawaii J Med Public Health       Date:  2015-04

8.  Understanding comorbidity: from epidemiological designs and model-fitting approaches to systems biology as a new tool.

Authors:  J K Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-01       Impact factor: 4.785

9.  Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.

Authors:  Pelle L Ishøy; Filip K Knop; Brian V Broberg; Lone Baandrup; Birgitte Fagerlund; Niklas R Jørgensen; Ulrik B Andersen; Egill Rostrup; Birte Y Glenthøj; Bjørn H Ebdrup
Journal:  BMJ Open       Date:  2014-01-08       Impact factor: 2.692

10.  A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population.

Authors:  Kevin Williamson; Karen Kilner; Nicola Clibbens
Journal:  J Nutr Sci       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.